Zostrix Zo-Rub Osteo topical analgesic cream

Zo-Rub Osteo, also widely known under the brand name Zostrix in other markets, is a specialized topical cream formulated with capsaicin to provide temporary relief from the pain associated with osteoarthritis and post-herpetic neuralgia. The brand has its roots in medical research focused on the analgesic properties of capsaicin, which is derived from chili peppers.

Historically, the Zostrix brand was developed by Link Medical Products in Australia and distributed globally through various pharmaceutical partnerships. In 2021, the healthcare giant iNova Pharmaceuticals acquired a portfolio of consumer healthcare brands from Link, which included the Zostrix/Zo-Rub range. This acquisition solidified iNova's position in the pain management sector across the Asia-Pacific region.

Currently, the brand is owned by iNova Pharmaceuticals, a large pharmaceutical group headquartered in Sydney, Australia. iNova itself is owned by a consortium of private equity investors, following its acquisition from Valeant (now Bausch Health) in 2017 and subsequent ownership transitions. The product is primarily manufactured in Australia to serve the domestic and regional Oceania markets.